Choi Su Yeon, Kim Hyung Woo, Jeon Sang Hoon, Kim Bit Na, Kang Nahyeon, Yeo Chang Dong, Park Chan Kwon, Kim Young Kyoon, Lee Yoon Ho, Lee Kyo Young, Lee Sug Hyung, Park Jong Y, Park Mi Sun, Yim Hyeon Woo, Kim Seung Joon
Division of Pulmonology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
The Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
In Vivo. 2019 May-Jun;33(3):945-954. doi: 10.21873/invivo.11563.
BACKGROUND/AIM: KRAS is one of the frequently mutated genes in human cancers and often relates with drug resistance and poor prognosis. PANAMutyper™ is a novel technology that integrates PNAClamp™ and PANA S-Melting™. In the present study, PANAMutyper™ and PNAClamp™ were compared for the detection of KRAS mutations using different samples of patients with malignant pleural effusion.
A total of 103 patients (including 56 lung adenocarcinoma, 10 lung squamous carcinoma, 17 small cell lung cancer, 3 large cell lung cancer, 3 stomach cancer, 2 ovarian cancer, and others) with malignant pleural effusion were investigated using matched tumor tissue, cell block, and pleural effusion samples. The diagnostic performance of these two methods was compared.
KRAS mutations were detected in 18 (17.5%) of 103 patients using tissue, cell block, and pleural effusion samples. All 18 patients with KRAS mutations were detected by PANAMutyper™ using any sample type, however, only 7 cases were detected by PNAClamp™. Among the subtypes of KRAS mutations, substitution in codon 12, 35G>T was the most frequent, followed by substitution in codon 12, 35G>A and codon 12, 34G>A. In pleural effusion specimens, PANAMutyper™ showed a better diagnostic performance compared to PNAClamp™.
PANAMutyper™ had a diagnostic superiority for the detection of KRAS mutations in patients with malignant pleural effusion compared to PNAClamp™, although there was a concordance between PANAMutyper™ and PNAClamp™ results. Therefore, PANAMutyper™ can be used for a more sensitive and accurate detection of KRAS mutations.
背景/目的：KRAS是人类癌症中常见的突变基因之一，常与耐药性和不良预后相关。PANAMutyper™是一种整合了PNAClamp™和PANA S-Melting™的新技术。在本研究中，比较了PANAMutyper™和PNAClamp™使用恶性胸腔积液患者的不同样本检测KRAS突变的情况。
共对103例恶性胸腔积液患者（包括56例肺腺癌、10例肺鳞癌、17例小细胞肺癌、3例大细胞肺癌、3例胃癌、2例卵巢癌及其他）进行研究，使用匹配的肿瘤组织、细胞块和胸腔积液样本。比较了这两种方法的诊断性能。
使用组织、细胞块和胸腔积液样本，在103例患者中的18例（17.5%）检测到KRAS突变。PANAMutyper™使用任何样本类型均检测到了所有18例KRAS突变患者，然而，PNAClamp™仅检测到7例。在KRAS突变亚型中，密码子12的35G>T替换最为常见，其次是密码子12的35G>A和密码子12的34G>A。在胸腔积液标本中，与PNAClamp™相比，PANAMutyper™表现出更好的诊断性能。
与PNAClamp™相比，PANAMutyper™在检测恶性胸腔积液患者的KRAS突变方面具有诊断优势，尽管PANAMutyper™和PNAClamp™的结果存在一致性。因此，PANAMutyper™可用于更灵敏、准确地检测KRAS突变。
